Alvotech (ALVO) Liabilities and Shareholders Equity (2020 - 2026)
Alvotech's (ALVO) quarterly Liabilities and Shareholders Equity came in at $1.4 billion in Q1 2026, up 14.11% YoY from $1.2 billion in Q1 2025, and down 4.43% on a QoQ basis from $1.5 billion in Q4 2025.
Alvotech (ALVO) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
Alvotech (ALVO) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $1.4 billion in Q1 2026.
- Quarterly Liabilities and Shareholders Equity rose 14.11% year-over-year to $1.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.7 billion (up 19.75% YoY) and the FY2025 annual result came in at $1.5 billion, up 21.75% from the prior year.
- Liabilities and Shareholders Equity declined to $1.4 billion in Q1 2026, from $1.5 billion in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.5 billion in Q4 2025 to a low of $774.5 million in Q2 2022.
- A 5-year average of $1.1 billion and a median of $1.1 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity jumped 38.54% — and 2026, when it rose 14.11%.
- Tracing ALVO's Liabilities and Shareholders Equity over 5 years: stood at $828.4 million in 2022, then advanced by 14.68% to $950.1 million in 2023, then increased by 28.56% to $1.2 billion in 2024, then increased by 21.75% to $1.5 billion in 2025, then decreased by 4.43% to $1.4 billion in 2026.
- The last three Liabilities and Shareholders Equity figures came in at $1.4 billion (Q1 2026), $1.5 billion (Q4 2025), and $1.4 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | 43.71 Bn |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 39.86 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 15.08 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 98.27 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 7.22 Bn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 35.04 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 5.36 Bn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 13.56 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 6.18 Bn |
| 10 | Alvotech | 1.30 Bn | 1.30 Bn | 5.09 Mn | 1.42 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.42 Bn |
| Dec 31, 2025 | 1.49 Bn |
| Sep 30, 2025 | 1.41 Bn |
| Jun 30, 2025 | 1.39 Bn |
| Mar 31, 2025 | 1.25 Bn |
| Dec 31, 2024 | 1.22 Bn |
| Sep 30, 2024 | 1.23 Bn |
| Jun 30, 2024 | 1.07 Bn |
| Mar 31, 2024 | 1.06 Bn |
| Dec 31, 2023 | 950.09 Mn |
| Jun 30, 2023 | 910.66 Mn |
| Mar 31, 2023 | 895.47 Mn |
| Dec 31, 2022 | 828.44 Mn |
| Jun 30, 2022 | 774.50 Mn |
| Dec 31, 2021 | 597.98 Mn |
| Dec 31, 2020 | 474.42 Mn |